Company: AZN
Filing Date: 2025-12-22
Form Type: 6-K
Source: 0001654954-25-014166
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-12-22
Form: 6-K
Chunk 7
---
 multinational cardiac safety study. Annals of Oncology. 2018; 29:646-653.

7. Huober J, et al. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial . J Clin Oncol. 2022; 40:2946-2956.

8. Masuda N, et al. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Res Treat. 2020; 180:135-146.

9. Gao H, et al. De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial. Presented ASCO Annual Meeting 2025.

10. Geyer C, et al. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. N Engl J Med . 2025; 392:249-57.

11. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4.2025.

12. National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer. Available at: https://seer.cancer.gov/statfacts/html/breast.html . Accessed December 2025.

13. Von Minckwitz G, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019; 380(7):617-628.

14. Zaborowski AM, et al. Neoadjuvant systemic therapy for breast cancer. Br J Surg. 2023; 110(7):765-772.

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to